Open AccessReal-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma
Author(s) -
Martin Metzenmacher,
Filippo Rizzo,
Kato Kambartel,
Jens Panse,
Diana Schaufler,
Matthias Scheffler,
Ivo Azeh,
Mathias Hoiczyk,
Amin T. Turki,
Judith Atz,
Hannes Buchner,
Christopher M. Hoffmann,
Daniel C. Christoph
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0424
Subject(s) - nintedanib , docetaxel , medicine , oncology , chemotherapy , adenocarcinoma , lung cancer , lung , idiopathic pulmonary fibrosis , cancer
Aim: This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Methods: Data were sourced retrospectively from seven German centers. Results: Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. Conclusion: To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy–immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.